ENDPOINTS NEWS35m
FDA ap­proves As­traZeneca’s asth­ma med­ica­tion Fasen­ra to treat rare au­toim­mune con­di­tion
A few months after a key label expansion, AstraZeneca’s asthma treatment Fasenra has received FDA approval to treat a rare ...
ENDPOINTS NEWS1h
Break­ing: Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal
The Federal Reserve made its long-anticipated interest rate cuts on Wednesday, lowering rates by a half of a percentage point ...
ENDPOINTS NEWS2h
Keytru­da adds new FDA ap­proval for a rare form of mesothe­lioma
Keytruda is already approved in more than 40 different oncology indications, but its latest label expansion is a first for ...
ENDPOINTS NEWS4h
Roivant makes an­oth­er deal, sell­ing Der­ma­vant to Organon for up to $1.2B
Roivant is once again reaping the benefits of its bespoke business model. This time, it's selling Dermavant to Organon for up ...
ENDPOINTS NEWS5h
With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out
Insilico Medicine reported Phase 2a results for its lead program, saying the study achieved its primary endpoint of safety ...
ENDPOINTS NEWS7h
No­vo Nordisk signs an­oth­er ge­net­ic med­i­cine pact, ink­ing deal with NanoVa­tion
Novo Nordisk is doubling down on its investment in genetic medicine-based biotechs, inking a new collaboration with a lipid ...
ENDPOINTS NEWS8h
Ex­clu­sive: For­mer Ama­zon Phar­ma­cy ex­ecs back Me­vo, a start­up bring­ing on­line pre­scrib­ing to Brazil
A startup in Brazil that lets people easily buy medicine online by combining a consumer-friendly experience with prescription ...
ENDPOINTS NEWS1d
No­var­tis’ Kisqali snags FDA ap­proval to re­duce re­cur­rence in pa­tients with ear­ly forms of breast can­cer
Novartis was already riding a wave of momentum with Kisqali, and now it has a new FDA nod to break into the early breast ...
ENDPOINTS NEWS1d
Con­duct­ing tri­als via rou­tine clin­i­cal prac­tice: FDA ex­plains how in new draft guid­ance
The FDA on Tuesday firmed up its position that in some limited circumstances, clinical trial data may be obtained from ...
ENDPOINTS NEWS1d
CD­MO Serán sets out to build first com­mer­cial fa­cil­i­ty, with a $200M in­vest­ment led by Bain Cap­i­tal
Small molecule contract manufacturer Serán Bioscience is building its first commercial-scale manufacturing facility, backed ...
ENDPOINTS NEWS1d
Co­herus warns of lim­it­ed can­cer drug sup­ply due to third-par­ty ‘ca­pac­i­ty con­straints’
Supplies of Coherus Biosciences' biosimilar version of the white blood cell-stimulating drug Neulasta will be “substantially ...
ENDPOINTS NEWS1d
Mer­ck and Dai­ichi’s re­ject­ed HER3 ADC clears a Phase 3 in cer­tain lung can­cers
Merck and Daiichi Sankyo have passed a Phase 3 with the lead antibody-drug conjugate from the megadeal they disclosed at last ...